ASX:BOT Botanix Pharmaceuticals (BOT) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Botanix Pharmaceuticals Stock (ASX:BOT) 30 days 90 days 365 days Advanced Chart Get BOT alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume1.63 million shsAverage VolumeN/AMarket CapitalizationA$912.82 millionP/E RatioN/ADividend Yield2.96%Price TargetN/AConsensus RatingN/A Company Overview Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. Botanix Pharmaceuticals Limited was incorporated in 1984 and is based in Leederville, Australia. Read More Receive BOT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Botanix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address BOT Stock News HeadlinesBotanix Pharmaceuticals Limited (BXPHF) - Yahoo FinanceJuly 11, 2025 | nz.finance.yahoo.comBOT - Botanix Pharmaceuticals Ltd Executives - MorningstarJuly 9, 2025 | morningstar.comMMiss This Window And You Miss EverythingThere’s a moment in every crypto cycle when everything just clicks — and that moment is now. This is the phase when momentum builds, news turns bullish, and markets ignite. Inside The Crypto Code Workshop, you’ll get the roadmap to ride this wave — and $10 in free Bitcoin just for showing up.July 18 at 2:00 AM | Crypto Swap Profits (Ad)Health Check: POTUS puts drug tariffs back on agenda… another case of TACO?July 9, 2025 | msn.comWhy Botanix, Dexus, Strickland, and Telix shares are charging higher todayJuly 9, 2025 | msn.comBotanix Pharmaceuticals Updates Sofdra Prescription MetricsJuly 8, 2025 | tipranks.comTuesday's HotCopper trends: Botanix Sofdra update, ClearVue board reshuffle | July 8July 8, 2025 | msn.comWhy Beetaloo, Botanix, Cobram Estate, and Origin Energy shares are falling todayJuly 8, 2025 | msn.comSee More Headlines BOT Stock Analysis - Frequently Asked Questions How were Botanix Pharmaceuticals' earnings last quarter? Botanix Pharmaceuticals Limited (ASX:BOT) announced its quarterly earnings results on Thursday, February, 28th. The company reported ($0.01) earnings per share (EPS) for the quarter. Botanix Pharmaceuticals had a negative net margin of 670.20% and a negative trailing twelve-month return on equity of 18.00%. What other stocks do shareholders of Botanix Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Botanix Pharmaceuticals investors own include Alphabet (GOOG), Meta Platforms (META), Arafura Rare Earths (ARU), Canopy Growth (CGC), Manning & Napier (MN), (STB.TO) (STB) and (YCB) (YCB). Company Calendar Last Earnings2/28/2019Today7/18/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:BOT CIKN/A Webwww.botanixpharma.com Phone+61-8-94820580FaxN/AEmployees11Year FoundedN/AProfitability EPS (Trailing Twelve Months)A($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-A$13.87 million Net Margins-670.20% Pretax MarginN/A Return on Equity-18.00% Return on Assets-12.74% Debt Debt-to-Equity RatioN/A Current Ratio22.21 Quick Ratio1.26 Sales & Book Value Annual SalesA$2.07 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow1.50 Book ValueA$0.07 per share Price / BookN/AMiscellaneous Outstanding Shares1,810,000,000Free FloatN/AMarket CapA$912.82 million OptionableNot Optionable Beta1.71 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (ASX:BOT) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTurn $1K into $50K with This DeFi GemTHREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | Sponsored“All the land that you see I will give to you and your offspring forever…”“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Botanix Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Botanix Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.